The Effects of C. lacerata on Insulin Resistance in Type 2 Diabetes Patients

Table 2

Clinical characteristics of the study population.

	Placebo group ()			C. lacerata group ()			value^b
	Week 0	Week 12	value^a	Week 0	Week 12	value^a
FPG (mg/dL)			0.477			0.765	0.352
2 hr Glc (mg/dL)			0.375			0.712	0.898
Hba1c (%)			0.047			0.016	0.287
F.C-pep (ng/mL)			0.689			0.001	0.440
P.C-pep (ng/mL)			0.764			0.001	0.136
F.PI (mcIU/mL)			0.336			0.014	0.347
P.PI (mcIU/mL)			0.678			0.009	0.109
HOMA-IR			0.432			0.072	0.199
HOMA-beta			0.957			0.089	0.593
QUICKI			0.541			0.287	0.741
TC (mg/dL)			0.184			0.401	0.300
LDL-C (mg/dL)			0.53			0.229	0.202
HDL-C (mg/dL)			0.027			0.711	0.523
TG (mg/dL)			0.149			0.166	0.220

Data are presented as (SD). ^aNonparametric paired Wilcoxon signed-rank test was used to compare baseline data to those at 12 weeks in each group. ^bMann-Whitney test was employed for analysis of difference between two groups. Statistically significant values are indicated ^awithin-group value < 0.05 and ^bbetween-group value < 0.05. FPG: fasting plasma glucose; 2 hr Glc: 2-hour plasma glucose; F.C-pep: fasting C-peptide; P.C-pep: postprandial C-peptide; F.PI: fasting plasma insulin; P.PI: postprandial plasma insulin; HOMA-IR: homeostasis model assessment for insulin resistance; QUICKI: quantitative insulin-sensitivity check index; TC: total cholesterol; LDL-C: LDL cholesterol; HDL-C: HDL cholesterol; TG: triglyceride; NS: nonsignificant.